Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Taxol
0.31623
Chemo
Chemotherapy
 -0.2908 0.56177
SK-BR-3 Taxol
1.0
Chemo
Chemotherapy
 -0.3401 0.58293
SK-BR-3 Topotecan
0.0010833
Topo I
Chemotherapy
 0.9528 -0.00945
SK-BR-3 Topotecan
0.0033333
Topo I
Chemotherapy
 0.9947 -0.00294
SK-BR-3 Topotecan
0.01
Topo I
Chemotherapy
 0.7630 0.00639
SK-BR-3 Topotecan
0.031667
Topo I
Chemotherapy
 0.1088 0.14919
SK-BR-3 Topotecan
0.1
Topo I
Chemotherapy
 -0.0100 0.16223
SK-BR-3 Topotecan
0.31623
Topo I
Chemotherapy
 -0.0775 0.25827
SK-BR-3 Topotecan
1.0
Topo I
Chemotherapy
 -0.1766 0.37995
SK-BR-3 Topotecan
3.1623
Topo I
Chemotherapy
 -0.2711 0.41925
SK-BR-3 Topotecan
10.0
Topo I
Chemotherapy
 -0.2234 0.36405
SK-BR-3 Etoposide
0.0010833
Topo II
Chemotherapy
 1.0284 -0.00047
SK-BR-3 Etoposide
0.0033333
Topo II
Chemotherapy
 1.0576 -0.00515
SK-BR-3 Etoposide
0.01
Topo II
Chemotherapy
 1.0002 0.00061
SK-BR-3 Etoposide
0.031667
Topo II
Chemotherapy
 0.9976 -0.00013
SK-BR-3 Etoposide
0.1
Topo II
Chemotherapy
 0.8882 0.00613
SK-BR-3 Etoposide
0.31623
Topo II
Chemotherapy
 0.6301 0.05893
SK-BR-3 Etoposide
1.0
Topo II
Chemotherapy
 0.0256 0.23805
SK-BR-3 Etoposide
3.1623
Topo II
Chemotherapy
 -0.1490 0.26854
SK-BR-3 Etoposide
10.0
Topo II
Chemotherapy
 -0.3169 0.50088
SK-BR-3 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 1.0111 0.00627
SK-BR-3 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 1.1797 -0.00056
SK-BR-3 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 1.1916 -0.00591
SK-BR-3 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 1.1244 -0.00148
SK-BR-3 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 1.1751 0.00120